台股 » 個股 » 旭富 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

旭富

(4119)
可現股當沖
  • 股價
    85.7
  • 漲跌
    ▲0.9
  • 漲幅
    +1.06%
  • 成交量
    82
  • 產業
    上市 生技醫療類股▼0.22%
  • 353人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
旭富 (4119)籌碼相關-永豐金-苓雅 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

永豐金-苓雅 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/1600.000.183.7084.00-0.1271-0.02%
2025/01/13183.5000.0083.9012690.37%
2025/01/10286.3000.0085.8022590.77%
2025/01/09289.1000.0088.5022510.79%
2025/01/080.389.9000.0089.800.32470.14%
2025/01/07189.9000.0089.8012470.40%
2024/12/20289.6500.0089.8022470.81%
2024/12/16190.101590.0790.30-14242-5.77%
2024/12/13191.6000.0090.6012380.42%
2024/12/12192.8000.0092.5012330.43%
2024/12/11294.1000.0094.0022290.87%
2024/12/10193.5000.0094.0012250.44%
2024/12/093.994.0800.0093.403.92241.73%
2024/12/06196.8000.0097.0012200.45%
2024/12/05297.6500.0097.4022180.92%
2024/12/041.597.5000.0097.801.52160.69%
2024/12/03098.0000.0097.8002160.01%
2024/12/02596.6800.0096.1052042.46%
2024/11/2900.00295.2596.20-2199-1.00%
2024/11/28594.7400.0095.0051972.53%
2024/11/272.294.7200.0094.702.21971.11%
2024/11/261.395.6400.0095.501.31930.67%
2024/11/25297.8000.0097.6021871.07%
2024/11/22197.5000.0097.5011810.55%
2024/11/21197.2000.0098.0011780.58%
2024/11/202.797.6900.0097.802.71721.58%
2024/11/180.495.0000.0096.000.41510.26%
2024/11/130.595.5000.0096.000.51360.39%
2024/11/112.193.8300.0093.302.11121.84%
2024/10/25089.3000.0089.4001170.00%
2024/10/09191.80191.7091.4001350.00%
2024/10/070.491.6000.0092.200.41350.29%
2024/10/010.189.5000.0091.000.11330.09%
2024/09/25188.8000.0089.7011410.71%
2024/09/180.388.1000.0088.000.31510.18%
2024/09/12187.3000.0087.5011560.64%
2024/09/10586.9000.0086.7051583.14%
2024/09/06086.5000.0086.5001590.00%
2024/09/040.187.1000.0087.000.11650.06%
2024/09/030.188.5000.0088.500.11640.06%
2024/08/30088.7000.0088.4001710.00%
2024/08/26089.3000.0089.0001750.01%
2024/08/2200.00588.9289.00-5177-2.82%
2024/08/19589.0000.0089.0051842.71%
2024/08/150.389.2400.0088.800.31880.15%
2024/08/120.190.5000.0089.900.12030.05%
2024/08/0700.00190.5090.50-1210-0.48%
2024/07/310.190.6000.0091.200.12040.05%
2024/07/3000.00190.8091.00-1204-0.49%
2024/07/2200.00190.7090.80-1202-0.49%
2024/07/19091.1000.0091.6002010.00%
2024/07/1500.00191.9092.80-1202-0.49%
2024/07/110.591.500.291.8091.800.32030.14%
2024/06/28090.2000.0090.4002050.00%
2024/06/26090.2000.0090.5002030.00%
2024/06/250.489.500.289.5089.500.22040.09%
2024/06/2400.005.389.8889.70-5.3204-2.57%
2024/06/200.290.30590.1690.20-4.8206-2.34%
2024/06/190.290.5000.0090.200.22050.11%
2024/06/17290.7000.0090.8022080.96%
2024/06/14190.0000.0090.1012100.47%
2024/06/130.490.6000.0090.000.42120.17%
2024/06/112.190.6100.0090.202.12140.98%
2024/06/070.292.7000.0093.100.22160.11%
2024/06/05492.8500.0092.9042201.81%
2024/06/031.192.2900.0092.401.12310.50%
2024/05/310.192.5000.0092.000.12300.02%
2024/05/280.192.7000.0092.500.12350.04%
2024/05/2700.00193.0093.10-1234-0.43%
2024/05/23291.40491.3091.30-2235-0.85%
2024/05/22492.4800.0092.4042351.70%
2024/05/2100.001892.2492.10-18235-7.64%
2024/05/203.292.550.193.5093.403.12331.32%
2024/05/16391.6300.0092.5032251.33%
2024/05/13191.6000.0091.8012320.43%
2024/05/09288.8500.0088.5022430.82%
2024/04/26788.9300.0089.0072452.85%
2024/04/190.188.00586.7086.40-5254-1.94%
2024/04/1700.00788.4088.40-7249-2.80%
2024/04/101589.2900.0089.50152615.73%
2024/04/0100.00289.0588.70-2257-0.78%
2024/03/27287.0000.0087.5022590.77%
2024/03/25287.6000.0087.6022610.77%
2024/03/20287.45187.6087.6012780.36%
2024/03/130.187.9000.0087.900.12850.02%
2024/03/111.189.051289.1889.10-10.9275-3.96%
2024/03/0800.000.191.5090.40-0.1273-0.05%
2024/03/05191.1000.0090.9012740.36%
2024/03/04390.9000.0090.9032741.09%
2024/02/27091.8000.0091.5002810.00%
2024/02/230.391.1000.0091.100.32830.11%
2024/02/20590.8000.0091.0052841.76%
2024/02/1500.004590.1489.90-45293-15.33%
2024/02/02090.5012690.1890.80-126290-43.36% 大賣/鉅額交易
2024/02/0113.192.6700.0092.3013.12994.38%
水星生醫*攜手旭富製藥 簽訂MTA開發抗癲癇藥物Anue鉅亨-2024/04/15
旭富新產能到位本季營運看增 觀音新廠產能再增5成Anue鉅亨-2023/10/03
星國阿茲海默三期順利解盲 旭富獨供原料藥營運吞補丸Anue鉅亨-2022/11/23
旭富 相關文章